(Q36028647)

11 August 2017

1 reference

title

Strategies for multiple signalling inhibition (English)

1 reference

11 August 2017

Tortora G

1

1 reference

11 August 2017

Bianco R

series ordinal

2

1 reference

11 August 2017

Daniele G

series ordinal

3

1 reference

11 August 2017

publication date

1 November 2004

1 reference

11 August 2017

published in

Journal of Chemotherapy

1 reference

11 August 2017

volume

16 Suppl 4

1 reference

11 August 2017

page(s)

41-43

1 reference

Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs.

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2004.16.SUPPLEMENT-1.41

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2004.16.SUPPLEMENT-1.41

Targeting epidermal growth factor receptor--are we missing the mark?

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2004.16.SUPPLEMENT-1.41

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2004.16.SUPPLEMENT-1.41

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2004.16.SUPPLEMENT-1.41

Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2004.16.SUPPLEMENT-1.41

10.1179/JOC.2004.16.SUPPLEMENT-1.41

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference